Ranbaxy assuages stakeholders over Mohali but more to come?
This article was originally published in Scrip
Ranbaxy Laboratories' top brass has assured stakeholders that the company is doing all it can to set right the concerns raised by the latest US FDA import alert against its Indian site in Mohali, but is keeping mum on reports suggesting its US site may also be facing certain unresolved good manufacturing practice (GMP) compliance issues.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.